egfr t790m Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 1 (1)

Interventional (1)

M.D. Anderson Cancer Center (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadEGFR

I am/have/hadcarcinoma

I am/have/hadserum glucose

I am/have/hadabsolute neutrophil count

I am/have/hadlung cancer

I am/have/hadmetastasis

I am/have/hadstereotactic radiosurgery

I am/have/hadstage ivb lung cancer ajcc v8

I am/have/hadtumor cells

I am/have/hadlung carcinoma

I am/have/hadcancer

I am/have/hadliver metastases

I am/have/hadmeasurable disease

I am/have/hadsmall cell lung cancer

I am/have/hadsystemic therapy

I am/have/haddeletion mutation

I am/have/hadlung carcinoma recurrent

I am/have/hadegfr t790m

I am/have/hadperiodic abstinence

I am/have/hadrecurrent non-small cell lung cancer

added new label for I am/have/had

more

I am looking for

I am looking fortyrosine

I am looking forsapanisertib

I am looking forhba1c

I am looking forgrowth factor

I am looking forblockade

I am looking forglycosylated hemoglobin

I am looking forosimertinib

I am looking fortotal bilirubin

I am looking forhemoglobin a1c

I am looking foralisertib

I am looking forkinase inhibitor

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Recruiting

Osimertinib With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

This phase Ib trial studies the side effects and best dose of alisertib or sapanisertib, in combination with osimertinib, in treating patients with EGFR mutated stage IIIB or IV non-small cell lung cancer that remains despite treatment with osimertinib (osimertinib resistant). Osimertinib, alisertib, and sapanisertib may stop the growth of …

EGFR

carcinoma

serum glucose

absolute neutrophil count

lung cancer

0 views
16 Feb, 2024
1 location

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.